UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE
13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a).
(Amendment No. __)*
CV THERAPEUTICS, INC.
-----------------------
(Name of Issuer)
COMMON STOCK ($0.001 Par Value)
---------------------------------
(Title of Class of Securities)
126667104
--------------
(CUSIP Number)
Stuart T. Weisbrod
Merlin BioMed Group, LLC
230 Park Avenue, Suite 928, New York, New York 10169
Tel: (646) 227-5200
with a copy to:
Jack P. Governale, Esq.,
Wolf, Block, Schorr and Solis-Cohen LLP
250 Park Avenue, Suite 1000, New York, New York 10036
Tel: (212) 883-4921
-----------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 31, 2000
--------------
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f), or 13d-1(g), check the following
box [ ].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosure
provided in a prior cover page.
<PAGE>
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 (the "Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 16 Pages
<PAGE>
CUSIP No. 126667104
Schedule 13D
Page 2 of 16
1 Name of Reporting Person
Stuart T. Weisbrod
S.S. or I.R.S. Identification No. of Above Person
2 Check the Appropriate Box If a Member of a Group
a. [ ]
b. [ ]
3 SEC Use Only
4 Source of Funds PF, OO.
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) [ ]
6 Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person:
7 Sole Voting Power 35,000
8 Shared Voting Power 883,400
9 Sole Dispositive Power 35,000
10 Shared Dispositive Power 883,400
11 Aggregate Amount Beneficially Owned by Each Reporting Person
918,400
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares*
[ ]
13 Percent of Class Represented By Amount in Row (11)
5.0%
14 Type of Reporting Person IN
<PAGE>
CUSIP No. 126667104
Schedule 13D
Page 3 of 16
1 Name of Reporting Person
Merlin BioMed Group, LLC
S.S. or I.R.S. Identification No. of Above Person
2 Check the Appropriate Box If a Member of a Group
a. [ ]
b. [ ]
3 SEC Use Only
4 Source of Funds OO.
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) [ ]
6 Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person:
7 Sole Voting Power 0
8 Shared Voting Power 883,400
9 Sole Dispositive Power 0
10 Shared Dispositive Power 883,400
11 Aggregate Amount Beneficially Owned by Each Reporting Person
883,400
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares*
[ ]
13 Percent of Class Represented By Amount in Row (11)
4.8%
14 Type of Reporting Person CO
<PAGE>
CUSIP No. 126667104
Schedule 13D
Page 4 of 16
1 Name of Reporting Person
Merlin BioMed, L.P.
S.S. or I.R.S. Identification No. of Above Person
2 Check the Appropriate Box If a Member of a Group
a. [ ]
b. [ ]
3 SEC Use Only
4 Source of Funds WC, OO.
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) [ ]
6 Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person:
7 Sole Voting Power 0
8 Shared Voting Power 234,200
9 Sole Dispositive Power 0
10 Shared Dispositive Power 234,200
11 Aggregate Amount Beneficially Owned by Each Reporting Person
234,200
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares*
[ ]
13 Percent of Class Represented By Amount in Row (11)
1.3%
14 Type of Reporting Person PN
<PAGE>
CUSIP No. 126667104
Schedule 13D
Page 5 of 16
1 Name of Reporting Person
Merlin BioMed II, L.P.
S.S. or I.R.S. Identification No. of Above Person
2 Check the Appropriate Box If a Member of a Group
a. [ ]
b. [ ]
3 SEC Use Only
4 Source of Funds WC, OO.
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) [ ]
6 Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person:
7 Sole Voting Power 0
8 Shared Voting Power 10,100
9 Sole Dispositive Power 0
10 Shared Dispositive Power 10,100
11 Aggregate Amount Beneficially Owned by Each Reporting Person
10,100
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares*
[ ]
13 Percent of Class Represented By Amount in Row (11)
0.1%
14 Type of Reporting Person PN
<PAGE>
CUSIP No. 126667104
Schedule 13D
Page 6 of 16
1 Name of Reporting Person
Merlin BioMed Advisors, LLC
S.S. or I.R.S. Identification No. of Above Person
2 Check the Appropriate Box If a Member of a Group
a. [ ]
b. [ ]
3 SEC Use Only
4 Source of Funds WC, OO.
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) [ ]
6 Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person:
7 Sole Voting Power 0
8 Shared Voting Power 326,900
9 Sole Dispositive Power 0
10 Shared Dispositive Power 326,900
11 Aggregate Amount Beneficially Owned by Each Reporting Person
326,900
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares*
[ ]
13 Percent of Class Represented By Amount in Row (11)
1.8%
14 Type of Reporting Person CO
<PAGE>
CUSIP No. 126667104
Schedule 13D
Page 7 of 16
1 Name of Reporting Person
Merlin BioMed Investment Advisors, LLC
S.S. or I.R.S. Identification No. of Above Person
2 Check the Appropriate Box If a Member of a Group
a. [ ]
b. [ ]
3 SEC Use Only
4 Source of Funds OO.
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) [ ]
6 Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person:
7 Sole Voting Power 0
8 Shared Voting Power 312,200
9 Sole Dispositive Power 0
10 Shared Dispositive Power 312,200
11 Aggregate Amount Beneficially Owned by Each Reporting Person
312,200
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares*
[ ]
13 Percent of Class Represented By Amount in Row (11)
1.7%
14 Type of Reporting Person CO
<PAGE>
Item 1. Security and Issuer.
This Statement relates to the common stock, par value $.001 per share (the
Common Stock"), of CV Therapeutics, Inc. (the "Company"). The principal
executive offices of the Company are located at 3172 Porter Drive, Palo Alto, CA
94304.
Item 2. Identity and Background.
The persons filing this statement are Stuart T. Weisbrod, a citizen of the
United States ("Weisbrod"), Merlin BioMed Group, LLC, a Delaware limited
liability company ("Merlin BioMed Group"), Merlin BioMed, L.P., a Delaware
limited partnership ("Merlin BioMed LP"), Merlin BioMed II, L.P., a Delaware
limited partnership (Merlin BioMed II"), Merlin BioMed Advisors, LLC, a Delaware
limited liability company ("Merlin BioMed Advisors"), and Merlin BioMed
Investment Advisors, LLC, a Delaware limited liability company ("Merlin BioMed
Investment Advisors", and collectively with Weisbrod, Merlin BioMed Group,
Merlin BioMed LP, Merlin BioMed II, and Merlin BioMed Advisors, the "Reporting
Persons"). The business address for Weisbrod and the location of the principal
executive offices for Merlin BioMed Group, Merlin BioMed LP, Merlin BioMed II,
Merlin BioMed Advisors and Merlin BioMed Investment Advisors is 230 Park Avenue,
Suite 928, New York, New York 10169.
Weisbrod is principally engaged in the business of investing in securities
as the managing member of the general partner of investment partnerships and as
the managing member of investment advisory companies. Weisbrod owns shares of
the Issuer directly. Weisbrod is the managing member of Merlin BioMed Group.
Merlin BioMed Group is the general partner of Merlin BioMed LP and Merlin BioMed
II. Weisbrod is the managing member of Merlin BioMed Advisors and of Merlin
BioMed Investment Advisors.
Merlin BioMed Group, of which Weisbrod is the managing member, serves as
the general partner of two investment partnerships, Merlin BioMed LP and Merlin
BioMed II.
Merlin BioMed LP, which has as its general partner Merlin BioMed Group, is
an investment partnership.
Merlin BioMed II, which has as its general partner Merlin BioMed Group, is
an investment partnership.
Merlin BioMed Advisors, of which Weisbrod is the managing member, is the
investment advisor to a managed account.
Merlin BioMed Investment Advisors, of which Weisbrod is the managing
member, is the investment advisor to three managed accounts.
A copy of the Joint Filing Agreement among the Reporting Persons is
attached hereto as Exhibit 1.
During the last five years, none of the persons listed above, or
identified as directors or officers of any such person, has been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors) or
has been a party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
Page 8 of 16 Pages
<PAGE>
Item 3. Source and Amount of Funds or Other Consideration.
(A) Weisbrod's acquisition of his shares for an aggregate purchase price of
$445,481 was paid in cash from Weisbrod's personal funds and on margin provided
by his brokerage firm.
(B) Merlin BioMed LP's acquisition of its shares for an aggregate purchase
price of $5,246,041 was paid in cash from its working capital and on margin
provided by its brokerage firm.
(B) Merlin BioMed II's acquisition of its shares for an aggregate purchase
price of $467,990 was paid in cash from its working capital and on margin
provided by its brokerage firm.
(B) Merlin BioMed Advisors' acquisition of shares for one managed account
for an aggregate purchase price of $9,298,232 was paid in cash from the working
capital of the managed account and on margin provided to such managed account by
its brokerage firm.
(B) Merlin BioMed Investment Advisors' acquisition of shares for three
managed accounts for an aggregate purchase price of $5,723,188 was paid in cash
from the working capital of the managed accounts and on margin provided to two
of the accounts by its brokerage firm.
Item 4. Purpose of Transaction.
The Reporting Persons have acquired shares of the Common Stock for
investment purposes.
Except as set forth herein, the Reporting Persons have no plans or
proposals which would relate to or result in:
(a) The acquisition by any person of additional securities of the
Company, or the disposition of securities of the Company;
(b) An extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Company or any of its subsidiaries;
(c) A sale or transfer of a material amount of assets of the Company
or any of its subsidiaries;
(d) Any change in the present board of directors or management of the
Company, including any plans or proposals to change the number or terms of
directors or to fill any existing vacancies on the board;
(e) Any material change in the present capitalization or dividend
policy of the Company;
(f) Any other material change in the Company's business or corporate
structure;
(g) Changes in the Company's charter, by-laws or instruments
corresponding thereto or other actions which may impede the acquisition of
control of the Company by any person;
(h) Causing a class of securities of the Company to be delisted from a
national securities exchange or to cease to be authorized to be quoted in an
Page 9 of 16 Pages
<PAGE>
inter-dealer quotation system of a registered national securities association;
(i) A class of equity securities of the Company becoming eligible for
termination of registration pursuant to Section 12(g)(4) of the Securities
Exchange Act of 1934, as amended; or
(j) Any action similar to any of those enumerated above.
The Reporting Persons intend to evaluate continuously the investment in the
Company described herein and, based on such evaluation, may determine at a
future date to change the current position with respect to any of the actions
described in clauses (a) through (j) of the instructions to Item 4 to Schedule
13D.
Item 5. Interest in Securities of the Issuer.
(a) and (b):
As of the close of business on May 31, 2000, the Reporting Persons may be deemed
to beneficially own in the aggregate 918,400 shares of Common Stock,
representing 5.0% of the Company's outstanding shares (based upon the 18,367,831
shares stated to be outstanding as of April 30, 2000 by the Company in the
Company's 10-Q filed with the Securities and Exchange Commission ("SEC").
(I) Weisbrod, with respect to the shares of Common Stock:
(a) Amount beneficially owned: 918,400
(b) Percent of class: 5.0%
(c) (i) Sole power to vote: 35,000
(ii) Shared power to vote: 883,400
(iii) Sole power to dispose: 35,000
(iv) Shared power to dispose: 883,400
Weisbrod owns directly (jointly, with his spouse) 35,000 shares of Common
Stock. Weisbrod is the managing member of Merlin BioMed Group, of Merlin BioMed
Investment Advisors, and of Merlin BioMed Advisors. Merlin BioMed Group is the
general partner of Merlin BioMed LP and of Merlin BioMed II.
(II) Merlin BioMed Group, with respect to the shares of Common Stock:
(a) Amount beneficially owned: 883,400
(b) Percent of class: 4.8%
(c) (i) Sole power to vote: 0
(ii) Shared power to vote: 883,400
(iii) Sole power to dispose: 0
(iv) Shared power to dispose: 883,400
(III) Merlin BioMed LP, with respect to the shares of Common Stock:
(a) Amount beneficially owned: 234,200
(b) Percent of class: 1.3%
(c) (i) Sole power to vote: 0
(ii) Shared power to vote: 234,200
(iii) Sole power to dispose: 0
(iv) Shared power to dispose: 234,200
(IV) Merlin BioMed II, with respect to the shares of Common Stock:
(a) Amount beneficially owned: 10,100
(b) Percent of class: 0.1%
(c) (i) Sole power to vote: 0
Page 10 of 16 Pages
<PAGE>
(ii) Shared power to vote: 10,100
(iii) Sole power to dispose: 0
(iv) Shared power to dispose: 10,100
(V) Merlin BioMed Advisors, with respect to the shares of Common Stock:
(a) Amount beneficially owned: 326,900
(b) Percent of class: 1.8%
(c) (i) Sole power to vote: 0
(ii) Shared power to vote: 326,900
(iii) Sole power to dispose: 0
(iv) Shared power to dispose: 326,900
(VI) Merlin BioMed Investment Advisors, with respect to the shares of Common
Stock:
(a) Amount beneficially owned: 312,200
(b) Percent of class: 1.7%
(c) (i) Sole power to vote: 0
(ii) Shared power to vote: 312,200
(iii) Sole power to dispose: 0
(iv) Shared power to dispose: 312,200
(c) The Reporting Persons effected the following purchases of the Issuer's
Common Stock in open market transactions:
Merlin BioMed LP bought:
(a) 8,000 shares at $31.9808 per share on 4/17/00; (b) 3,000 shares at $30.9471
per share on 4/17/00; (c) 1,000 shares at $36.00 per share on 4/26/00; (d) 1,100
shares at $34.00 per share on 4/27/00; (e) 5,600 shares at $37.50 per share on
4/28/00; (f) 800 shares at $39.125 per share on 4/28/00; (g) 2,100 shares at
$39.2139 per share on 4/28/00; (h) 3,700 shares at $40.2975 per share on
4/28/00; (i) 3,400 shares at $34.125 per share on 5/12/00; (j) 14,400 shares at
$41.0881 per share on 5/16/00; (k) 15,000 shares at $38.5781 per share on
5/17/00; (l) 4,200 shares at $36.625 per share on 5/18/00; (m) 3,800 shares at
$34.500 per share on 5/23/00; (n) 4,400 shares at $38.041 per share on 5/26/00;
(o) 7,000 shares at $37.3969 per share on 5/30/00;(p) 6,600 shares at $38.928
per share on 5/31/00; (q) 7,000 shares at $40.884 per share on 5/31/00; (r)
2,100 shares at $40.1225 per share on 6/1/00;
Merlin BioMed II bought:
(a) 2,000 shares at $47.0625 per share on 4/3/00;(b) 5,000 shares at $50.1875
per share on 4/10/00; (c) 100 shares at $39.2139 per share on 4/28/00; (d) 100
shares at $40.2975 per share on 4/28/00; (e) 200 shares at $37.50 per share on
4/28/00; (f) 600 shares at $41.0881 per share on 5/15/00; (g) 600 shares at
$38.5781 per share on 5/17/00; (h) 100 shares at 34.50 per share on 5/23/00; (i)
200 shares at $38.041 per share on 5/26/00; (j) 300 shares at $39.928 per share
on 5/31/00; (k) 300 shares at $40.884 per share on 5/31/00; (l) 300 shares at
$37.3989 per share on 5/30/00;
Merlin BioMed Advisors, on behalf of a managed account for Merlin BioMed
International, Ltd., sold:
(a) 5,000 shares at $50.1875 per share on 4/10/00; and bought:
(b) 12,000 shares at $31.9808 per share on 4/17/00; (c) 3,400 shares at $30.9471
per share on 4/17/00; (d) 1,400 shares at $34.00 per share on 4/27/00; (e) 3,000
shares at $39.2139 per share on 4/28/00;(f) 5,300 shares at $40.2975 per share
on 5/3/00; (g) 1,200 shares at $39.125 per share on 4/28/00; (h) 7,900 shares at
$37.50 per share on 4/28/00; (i) 1,500 shares at $36.00 per share on 4/26/00;(j)
4,400 shares at $34.125 per share on 5/12/00; (k) 20,100 shares at $41.0881 per
share on 5/16/00; (l) 21,000 shares at $38.5781 per share on 5/17/00; (m) 5,800
Page 11 of 16 Pages
<PAGE>
shares at $36.625 per share 5/18/00; (n) 5,300 shares at $ 34.50 per share on
5/23/00; (o) 2,900 shares at $33.5976 per share on 5/24/00;(p) 6,200 shares at
$38.041 per share on 5/38/00; (q) 9,700 shares at $40.884 per share on 5/31/00;
(r) 9,200 shares at $38.928 per share on 5/31/00; (s) 9,800 shares at $37.3969
per share on 5/30/00; (t) 2,900 shares at $40.1225 per share on 6/1/00;
Merlin BioMed Investment Advisors, on behalf of a first managed account, bought:
(a) 3,500 shares at $30.9471 per share on 4/17/00; (b) 900 shares at $40.2976
per share on 4/28/00; (c) 1,300 shares at $37.50 per share on 4/28/00; (d) 3,300
shares at $41.0881 per share on 5/16/00; (e) 3,400 shares at $38.5781 per share
on 5/17/00; (f) 800 shares at $34.50 per share on 5/23/00; (g) 1,000 shares at
$38.041 per share on 5/26/00; (h) 1,500 shares at $38.928 per share on 5/31/00;
Merlin BioMed Investment Advisors, on behalf of a second managed account,
bought:
(a) 3,000 shares at $30.9471 per share on 4/17/00; (b) 10,000 shares at $39.2139
per share on 4/28/00; (c) 2,600 shares at $41.0881 per share on 5/18/00; (d)
5,000 shares at $37.3969 per share on 5/30/00; (e) 3,600 shares at $38.928 per
share on 5/31/00; (f) 1,300 shares at $38.928 per share on 5/31/00; (g) 3,000
shares at $40.884 per share on 5/31/00;
Merlin BioMed Investment Advisors, on behalf of a third managed account, bought:
(a) 5,000 shares at $28.750 per share on 4/17/00; (b) 6,000 shares at $31.0808
per share on 4/20/00; (c) 1,000 shares at $32.250 per share on 5/15/00; (d)
9,000 shares at $41.0881 per share on 5/19/00; (e) 4,100 shares at $38.028 per
share on 6/5/00;
(d) Merlin BioMed Advisors manages investment transactions for and on behalf of
an offshore investment fund, Merlin BioMed International, Ltd., pursuant to an
investment advisory contract. Merlin BioMed Investment Advisors manages
investment transactions for three managed accounts, pursuant to separate
investment advisory contracts. Other than as disclosed, no other person has the
right to receive or the power to direct the receipt of dividends from, or the
proceeds from the sale of any Common Shares which the Reporting Persons may be
deemed to beneficially own.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
Weisbrod is the managing member of Merlin BioMed Group, which is the
general partner for each of Merlin BioMed and Merlin BioMed II. Weisbrod is the
managing member of Merlin BioMed Investment Advisors and of Merlin BioMed
Advisors.
A portion of the shares of Common Stock purchased by Weisbrod, Merlin
BioMed LP, Merlin BioMed II, and Merlin BioMed Advisors was purchased by using
margin provided by Morgan Stanley Dean Witter & Co., and a portion of the shares
of Common Stock purchased by Merlin BioMed Investment Advisors for two of the
three managed accounts was purchased by using margin provided by Goldman, Sachs
& Co., all in accordance with the standard margin account terms of such firms.
Item 7. Material to be filed as Exhibits.
The following is filed herewith as an exhibit:
Page 12 of 16 Pages
<PAGE>
Exhibit 1 Joint Filing Agreement among Stuart T. Weisbrod, Merlin BioMed
Group, LLC, Merlin BioMed, L.P., Merlin BioMed II, L.P., Merlin
Investment Advisors, LLC, and Merlin BioMed Advisors, LLC, dated
June 12, 20000.
Page 13 of 16 Pages
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: June 12, 2000
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
MERLIN BIOMED GROUP, LLC
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED, L.P.
by: Merlin BioMed Group, LLC
its general partner
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED II, L.P.
by: Merlin BioMed Group, LLC
its general partner
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED INVESTMENT ADVISORS, LLC
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED ADVISORS, LLC.
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
Page 14 of 16 Pages
<PAGE>
EXHIBIT INDEX
-------------
Exhibits
Exhibit 1 Joint Filing Agreement among Stuart T. Weisbrod, Merlin BioMed
Group, LLC, Merlin BioMed, L.P., Merlin BioMed II, L.P., Merlin
Investment Advisors, LLC, and Merlin BioMed Advisors, LLC, dated
June 12, 20000.
Page 15 of 16 Pages
<PAGE>
EXHIBIT 1
---------
JOINT FILING AGREEMENT
The undersigned hereby agree that this Statement on Schedule 13D with
respect to the beneficial ownership of shares of Common Stock, par value $.001,
of CV Therapeutics, Inc. is filed jointly, on behalf of each of them.
Dated: June 12, 2000
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
MERLIN BIOMED GROUP, LLC
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED, L.P.
by: Merlin BioMed Group, LLC
its general partner
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED II, L.P.
by: Merlin BioMed Group, LLC
its general partner
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED INVESTMENT ADVISORS, LLC
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
MERLIN BIOMED ADVISORS, LLC.
/s/ Stuart T. Weisbrod
-----------------------------
Stuart T. Weisbrod
Title: Managing Member
Page 16 of 16 Pages
